FENC Fennec Pharmaceuticals Inc.

NEUTRAL Impact: 2/10 PRESS-RELEASE
Horizon days Filed May 7, 2026 Processed 1mo ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+20d
FENC ▲ +32.46% at T+20d
NEUTRAL call ✓ call won +32.46% · α vs SPY +29.33% · entry $6.90 → $9.14
Next anchor: T+60d in 7w
Currently $9.00 · +30.43% from $6.90 entry
Entry anchored
May 7, 2026
via day open
T+1d
+0.43%
call +0.43% · α -0.40%
$6.93
settled 5w ago
T+5d
-1.88%
call -1.88% · α -3.39%
$6.77
settled 4w ago
T+20d
+32.46%
call +32.46% · α +29.33%
$9.14
settled 8d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Fennec Pharmaceuticals announced it will release Q1 2026 financial results on May 14, 2026. The press release contains no financial data for the current period; the synthetic earnings context shows a Q4 2025 EPS miss of -499.9% vs consensus, but this is not part of the actual filing. The stock has historically declined following FENC reports, with an average T+20 loss of -13.08% across prior calls.

Actionable Insight

This is a routine earnings date announcement with no financial content. Monitor the May 14 release for actual Q1 2026 results and any guidance updates. Given the stock's historical negative drift following FENC reports, traders should watch for potential downside if results disappoint.

Key Facts

  • Q1 2026 earnings release scheduled for May 14, 2026 before market open
  • Conference call and webcast at 8:30 a.m. ET on May 14, 2026
  • No financial results or guidance included in this press release
  • Historical performance shows average T+20 loss of -13.08% on prior FENC reports

Financial Impact

No financial data in this filing

Risk Factors

  • No current financial data to assess — risk of adverse results on May 14
  • Historical pattern of negative stock movement following FENC filings

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289755
13 reports for FENC
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +20.32%Feb 28, 2026
Filters
Rows
Reports for FENC — sortable, filterable
Type Now
May 22, 2026
21d ago
8-K
NEUTRAL ★ 4/10
$9.89 $9.88▼ −0.10%▼ −1.18%$9.00 (−9.00%)
May 18, 2026
25d ago
8-K
NEUTRAL ★ 2/10
$9.76 $9.97▲ +2.15%▼ −0.15%$9.00 (−7.79%)
May 14, 2026
4w ago
Press Release
BULLISH ★ 6/10
$9.24 $9.97▲ +7.90%▲ +8.62%$9.00 (−2.60%)
May 7, 2026
5w ago
Press Release
NEUTRAL ★ 2/10
$6.90 $6.77▼ −1.88%▼ −3.39%$9.00 (+30.43%)
Apr 28, 2026
6w ago
8-K
NEUTRAL ★ 2/10
$6.26 $7.18▲ +14.70%▲ +11.59%$9.00 (+43.77%)
Apr 22, 2026
7w ago
8-K
NEUTRAL ★ 3/10
$6.66 $6.26▼ −6.01%▼ −7.48%$9.00 (+35.14%)
Apr 7, 2026
9w ago
8-K
NEUTRAL ★ 4/10
$6.49 $6.50▲ +0.15%▼ −3.36%$9.00 (+38.67%)
Apr 7, 2026
9w ago
Press Release
NEUTRAL ★ 4/10
$6.32 $6.25▼ −1.11%▼ −6.44%$9.00 (+42.41%)
Mar 24, 2026
11w ago
Press Release
BULLISH ★ 8/10
$6.02 $6.15▲ +2.16%▲ +2.58%$9.00 (+49.50%)
Mar 18, 2026
12w ago
Press Release
NEUTRAL ★ 3/10
$7.47 $6.17▼ −17.40%▼ −16.69%$9.00 (+20.48%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (48h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access